Header Logo

Connection

VASSILIKI A PAPADIMITRAKOPOULOU to Head and Neck Neoplasms

Back to Details
This is a "connection" page, showing publications VASSILIKI A PAPADIMITRAKOPOULOU has written about Head and Neck Neoplasms.
VASSILIKI A PAPADIMITRAKOPOULOU
Connection Strength
1.776
Head and Neck Neoplasms
  1. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80.
    View in: PubMed
    Score: 0.178
  2. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15; 117(10):2112-9.
    View in: PubMed
    Score: 0.131
  3. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14.
    View in: PubMed
    Score: 0.122
  4. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer. 2005 Mar 01; 103(5):952-9.
    View in: PubMed
    Score: 0.088
  5. Focus on head and neck cancer. Cancer Cell. 2004 Apr; 5(4):311-6.
    View in: PubMed
    Score: 0.082
  6. Chemoprevention of head and neck cancer. Curr Oncol Rep. 2003 Mar; 5(2):152-7.
    View in: PubMed
    Score: 0.076
  7. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer. 2023 03 01; 129(5):714-727.
    View in: PubMed
    Score: 0.075
  8. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12):1605-10.
    View in: PubMed
    Score: 0.075
  9. Chemoprevention of head and neck cancer: an update. Curr Opin Oncol. 2002 May; 14(3):318-22.
    View in: PubMed
    Score: 0.072
  10. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res. 2001 Oct; 7(10):3127-34.
    View in: PubMed
    Score: 0.069
  11. Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer. Int J Cancer. 2000 Dec 15; 88(6):852-5.
    View in: PubMed
    Score: 0.065
  12. Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal. Curr Opin Oncol. 2000 May; 12(3):240-5.
    View in: PubMed
    Score: 0.063
  13. Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. Clin Cancer Res. 1998 Mar; 4(3):539-44.
    View in: PubMed
    Score: 0.054
  14. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 03 01; 110(3).
    View in: PubMed
    Score: 0.054
  15. Retinoids in head and neck chemoprevention. Proc Soc Exp Biol Med. 1997 Nov; 216(2):283-90.
    View in: PubMed
    Score: 0.053
  16. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Cancer J Sci Am. 1997 Mar-Apr; 3(2):92-9.
    View in: PubMed
    Score: 0.050
  17. Biology of oral premalignant lesions: concepts and implications for chemoprevention. Eur J Cancer Prev. 1996 Dec; 5 Suppl 2:87-93.
    View in: PubMed
    Score: 0.049
  18. Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. Cancer Metastasis Rev. 1996 Mar; 15(1):53-76.
    View in: PubMed
    Score: 0.047
  19. Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck. Head Neck. 2014 Apr; 36(4):474-80.
    View in: PubMed
    Score: 0.039
  20. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.035
  21. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res. 2011 Apr 01; 17(7):1815-27.
    View in: PubMed
    Score: 0.033
  22. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
    View in: PubMed
    Score: 0.032
  23. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila). 2009 Sep; 2(9):823-9.
    View in: PubMed
    Score: 0.030
  24. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008 Feb; 26(1):81-7.
    View in: PubMed
    Score: 0.026
  25. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
    View in: PubMed
    Score: 0.024
  26. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002 Jul 15; 95(2):322-30.
    View in: PubMed
    Score: 0.018
  27. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol. 2001 Jun 15; 19(12):3010-7.
    View in: PubMed
    Score: 0.017
  28. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001 Apr 01; 91(7):1316-23.
    View in: PubMed
    Score: 0.017
  29. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst. 2000 Jan 05; 92(1):69-73.
    View in: PubMed
    Score: 0.015
  30. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene. 1998 Nov 05; 17(18):2313-22.
    View in: PubMed
    Score: 0.014
  31. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998 Oct 21; 90(20):1545-51.
    View in: PubMed
    Score: 0.014
  32. Chemoprevention in head and neck cancer: basic science and clinical application. Semin Radiat Oncol. 1998 Oct; 8(4):292-301.
    View in: PubMed
    Score: 0.014
  33. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Apr; 16(4):1325-30.
    View in: PubMed
    Score: 0.014
  34. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst. 1997 Feb 05; 89(3):257-8.
    View in: PubMed
    Score: 0.013
  35. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res. 1996 Jun 01; 56(11):2519-21.
    View in: PubMed
    Score: 0.012
  36. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res. 2004 Jan 15; 10(2):658-67.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.